| 2006-02-14: |
GlaxoSmithKline Announces Commencement of Eltrombopag Phase III Worldwide Clinical Trial in Adults With Previously - Treated Idiopathic Thrombocytopenic Purpura
London, England and Philadelphia, Pennsylvania ( PRN/ots ) - GlaxoSmithKline plc ( GSK ) announced today the commencement of a worldwide clinical trial to investigate the safety and efficacy of eltrombopag ( SB - 497115 - GR ) as a once - daily orally - administered drug for adult patients with previously - treated (...) |
| 2008-05-06: |
Making a Real Difference to the Lives of Asthma Patients
Southampton, England ( PRN/ots ) - - Leading Asthma Expert Calls for Action On the occasion of World Asthma Day on 6 May, leading asthma expert Professor Stephen Holgate from the University of Southampton ( UK ) says: "I am delighted that the theme of this (...) |
| 2006-08-09: |
Go - ahead for the Scientific Award 2007 / The BMW Group offers support worth EUR 70,000 to talented young researchers from all disciplines worldwide
Munich ( na Originaltextservice ) - The BMW Group is inviting young academics from all over the world to submit their entries for the prize for up - and - coming scientists - the Scientific Award 2007. The motto of the award is "Passion for Innovation", and prizes are presented (...) |
| 2004-09-01: |
T - Cell Lymphoma Patients Achieve Long Lasting Responses With Genmab's HuMax - CD4
Copenhagen, Denmark ( PRN/ots ) - Genmab A/S ( CSE: GEN ) announced today that cutaneous T - cell lymphoma ( CTCL ) patients in the HuMax - CD4 Phase II studies achieved long lasting responses, with an average response duration of more than 6.6 months. This duration of response data (...)
Conference Call Genmab will hold a conference call to discuss the news today Wednesday, September 1, 2004 at: 3:30 pm CET 2:30 pm BST 9:30 am EDT The conference call will be held in English. The dial in numbers are as follows: +1 - 800 - 500 - 0177 ( in the US ) and ask for the Genmab conference call +1 - 719 - 457 - 2679 ( outside the US ) and ask for the Genmab conference call
About Genmab A/S Genmab A/S is a biotechnology company that creates and develops human antibodies for the treatment of life - threatening and debilitating diseases. Genmab has numerous products in development to treat cancer, infectious disease, rheumatoid arthritis and other inflammatory conditions, and intends to continue assembling a broad portfolio of new therapeutic products. At present, Genmab has multiple partnerships to gain access to disease targets and develop novel human antibodies including agreements with Roche and Amgen. A broad alliance provides Genmab with access to Medarex, Inc.'s array of proprietary technologies, including the UltiMAb( TM ) platform for the rapid creation and development of human antibodies to virtually any disease target. Genmab is headquartered in Copenhagen, Denmark, and has operations in Utrecht, The Netherlands, and Princeton, New Jersey in the US. For more information about Genmab, visit http://www.genmab.com . Except for the historical information presented herein, matters discussed in this press release are forward looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements, e.g. unforeseen exchange rate and interest rate fluctuations, delayed or unsuccessful development projects. Statements that are not historical facts, including statements preceded by, followed by, or that include the words "believes"; "anticipates"; "plans"; "expects"; "estimates"; or similar statements are forward - looking statements. Genmab is not under an obligation to up - date statements regarding the future following the publication of this release; nor to confirm such statements in relation to actual results, unless this is required by law. HuMax - CD4( TM ) is a trademark of Genmab A/S. UltiMAb( TM ) is a trademark of Medarex, Inc. Web site: http://www.genmab.com ots Originaltext: Genmab A/S Im Internet recherchierbar: http://www.presseportal.de Contact: Rachel Gravesen, VP IR&PR of Genmab A/S, +45 - 33 - 44 - 77 - 34, or mobile, +45 - 25 - 40 - 30 - 01, rcg@genmab.com |
| 2009-03-31: |
Wyeth Submits Marketing Application to FDA for its 13 - Valent Vaccine for the Prevention of Pneumococcal Disease in Infants and Toddlers
Collegeville, Pennsylvania ( PRN/ots ) - - Candidate vaccine designed to protect against the 13 most prevalent serotypes associated with pneumococcal disease - Wyeth Pharmaceuticals, a division of Wyeth ( NYSE: WYE ), announced today that it has submitted a Biologic License Application ( BLA ) to the U.S. (...) |
| 2010-11-08: |
Study Shows Cardiovascular Deaths in Europe Could Be Prevented
Prague, November 8 ( PRN/ots ) - Cardiovascular disease ( CVD ) is the leading cause of death in Europe, killing an estimated 4.3 million people each year.[i] Results from a large pan - European study announced today indicate that many of these deaths could be avoided if (...) |
| 2010-06-11: |
First Dedicated Virtual Community for Immune Thrombocytopenia ( ITP ) Patients Launched Today
Zug, Switzerland, June 11, 2010 ( PRN/ots ) - Amgen ( Europe ) today launched ITPvillage.com, a dedicated website bringing together patients, healthcare professionals and those who care for people affected by ITP, at the 15th Congress of European Hematology Congress in Barcelona, Spain. For many patients living (...) |
| 2010-11-10: |
Stallergenes Welcomes Ares Life Sciences as a New Reference Shareholder
Antony, France, November 10 ( PRN/ots ) - Following the announcement that Wendel had entered exclusive negotiations with Ares Life Sciences on October 28, 2010, with a view to selling its entire stake ( around 46 Prozent ) in Stallergenes, the company's Works Council met on November 10, 2010. (...) |
| 2008-11-27: |
European Committee for Human Medicinal Products ( CHMP ) Issues Positive Opinion for Once - Daily PREZISTA( R ) ( Darunavir ) as Part of Combination Therapy for Treatment - Naïve Adults With HIV - 1
Cork, Ireland, November 27 ( PRN/ots ) - The Committee for Human Medicinal Products ( CHMP ) has issued a positive opinion recommending approval for once - daily dosing of 800 mg PREZISTA( R ) ( darunavir ) with low - dose ritonavir as part of combination therapy in treatment - naïve adults ( those who (...) |
| 2007-11-02: |
Roche's Oral Polymerase Inhibitor Shows Robust Antiviral Efficacy in Treatment of Chronic Hepatitis C
Basel, Switzerland, November 2 ( PRN/ots ) - - Roche Progresses R1626 Into Phase IIb Study Called POLI 1 R1626, one of Roche's new investigational drugs for hepatitis C ( HCV ), has shown promising antiviral efficacy when given in combination with PEGASYS( R ) ( peginterferon alfa - 2a (...) |
| 2008-11-07: |
Atrial Fibrillation Found to be Common in Patients With Atherothrombosis, Increases Risk of Cardiovascular Death, Heart Attack and Stroke
Tokyo, November 7 ( PRN/ots ) - - Large, International REACH Registry Also Shows Many Patients With Atrial Fibrillation are Undertreated With Antiplatelet and Anticoagulant Therapies A significant portion of patients with atherothrombosis also have atrial fibrillation ( AF ), greatly increasing their risk for cardiovascular death, heart (...) |
| 2005-01-26: |
Web Cast of Landmark, Independent Trial Data from Major Breast Cancer Meeting
St. Gallen, Switzerland ( PRN/ots ) - - Promising News for Breast Cancer Patients - Web Cast Briefing Available at http://www.ibcsg.org/index.shtm
WHAT: BIG 1 - 98: First results and implications. A landmark, independent study found that letrozole, a leading aromatase inhibitor also (...)
Web Site: http://www.ibcsg.org/index.shtm ots Originaltext: IBCSG Im Internet recherchierbar: http://www.presseportal.de Contact: Nadia Munarini, PhD, IBCSG, +41 - 31 - 389 - 92 - 27, or nadia.munarini@ibcsg.org; Rum Ekhtiar of Ruder Finn, +1 - 212 - 593 - 5821, or ekhtiarr@ruderfinn.com, for IBCSG |
| 2007-05-18: |
Data Show ENBREL Significantly Improved Nail Psoriasis in Patients with Moderate to Severe Plaque Psoriasis
Vienna, Austria ( PRN/ots ) - Wyeth Pharmaceuticals, a division of Wyeth ( NYSE: WYE ), today announced new data that showed that, in moderate to severe plaque psoriasis patients, ENBREL( R ) ( etanercept ) reduced the severity of nail psoriasis by more than 28 percent at 12 weeks (...) |
| 2005-11-14: |
New Ascot - BPLA Substudy Shows Coversyl's Cardioprotective Benefits go Beyond Blood Pressure Reduction
Dallas, Texas, November 14 ( PRN/ots ) - - CAFÉ Study Shows Central Aortic Pulse Pressure Important Determinant of Cardiovascular Outcomes A new sub - study of the Anglo - Scandinavian Cardiac Outcomes Trial ( ASCOT )( 1 ), presented during a late breaking clinical trial session of the American Heart (...) |
| 2010-10-12: |
ArQule and Daiichi Sankyo Expand Drug Discovery Collaboration in Oncology
Woburn, Massachusetts ( PRN/ots ) - ArQule, Inc. and Daiichi Sankyo Co., Ltd. ( TSE 4568 ) today announced the expansion of their research, development and license agreement for the discovery of novel kinase inhibitors in the field of oncology. This expanded agreement establishes a third therapeutic target, (...) |
| 2008-09-18: |
Enbrel( R ) Shown to Deliver Long - Lasting Improvements in Psoriasis Patients' Quality of Life
Maidenhead, England ( PRN/ots ) - - New Study Results Further Support That Enbrel Effectively Clears Skin, Reduces the Prevalence of Depression and Anxiety and Improves Patients' Quality of Life Data demonstrating the significant positive impact of Enbrel ( etanercept ) on the quality of life of (...) |
| 2011-03-29: |
Institut Pasteur Shanghai Announces the Creation of its Global Biotech Accelerator Advance BioChina
Biovision, Lyon, France ( PRN/ots ) - Institut Pasteur of Shanghai announces today the creation of its global biotech accelerator company Advance BioChina. Advance BioChina is an R&D - focused for - profit organization that positions itself as the gateway to China for global biotech companies. Advance BioChina (...) |
| 2005-06-02: |
Anadys Pharmaceuticals Announces Exclusive Collaboration With Novartis to Develop and Commercialize ANA975 and Additional TLR7 - Based Therapeutics for Hepatitis C and Hepatitis B
San Diego, California ( PRN/ots ) - - Total Partnership Valued at Up to USD$570 Million in Upfront and Potential Milestone Payments Anadys Pharmaceuticals, Inc. ( Nasdaq: ANDS ) announced today that it has entered into an exclusive global license and co - development agreement with Novartis to (...) |
| 2008-06-05: |
SemBioSys Demonstrates Functionality of its Safflower Produced Apo AI( Milano )
Calgary, Canada ( PRN/ots ) - - Company Achieves Important Milestone in Development of Next Generation Cardiovascular Drug SemBioSys Genetics Inc. ( TSX:SBS ), a biotechnology company dedicated to developing a portfolio of therapeutic proteins for metabolic and cardiovascular diseases, today announced that it has demonstrated that (...) |
| 2009-06-08: |
Final Call for Entries to the 'Excellence in Epilepsy' Journalism Award
Brussels ( PRN/ots ) - The 'Excellence in Epilepsy' Journalism Award - an initiative of the International Bureau for Epilepsy ( IBE ) and UCB - invites journalists from around the world to submit stimulating, informed and compelling news and feature stories on epilepsy. The award seeks to increase awareness (...) |
| 2008-07-09: |
European Commission Announces Marketing Authorisation for 50mg Once Weekly Enbrel( R ) for Patients With Moderate - to - Severe Psoriasis
Maidenhead, England ( PRN/ots ) - - New Dosing Option Provides Greater Flexibility and Convenience for Patients to Effectively Control the Debilitating Symptoms of their Condition( 1 ) The European Commission announced today a new 50 mg Enbrel( R ) ( etanercept ) once weekly dosage regimen as an alternative to (...) |
| 2007-06-18: |
Janssen - Cilag International NV Submits Marketing Authorization Application in Europe for New Antibiotic
Beerse, Belgium ( PRN/ots ) - Janssen - Cilag International NV has submitted a Marketing Authorization Application ( MAA ) to the European Medicines Agency ( EMEA ) for ceftobiprole, an investigational antibiotic for the treatment of complicated skin and soft tissue infections ( cSSTI ) including diabetic foot infections. Ceftobiprole, the first (...) |
| 2011-03-04: |
ONGLYZA( R ) Becomes the First DPP - 4 Inhibitor Available for Use in Europe
Paris and London ( PRN/ots ) - Bristol - Myers Squibb Company ( http://www.bms.com ) and AstraZeneca ( http://www.astrazeneca.com ) today announced that the European Commission has approved a label update for ONGLYZA( R ) ( saxagliptin ) in the treatment of adults with type 2 diabetes who have moderate or severe renal impairment. (...) |
| 2006-11-09: |
Two - Year Data for Abatacept Demonstrate Continued Efficacy in Adults With Rheumatoid Arthritis
Paris, November 9 ( PRN/ots ) - - Data to be Presented at Upcoming American College of Rheumatology Annual Meeting Bristol - Myers Squibb Company ( NYSE: BMY ) today announced that two - year data from three Phase III pivotal trials demonstrate the long - term efficacy of abatacept (...) |
| 2010-12-14: |
Ocean Nutrition Canada Limited Announces Strategic Alliance with Wilmar International Limited - the World's Largest Omega - 3 EPA/DHA Food Company
Dartmouth, Canada ( PRN/ots ) - Ocean Nutrition Canada Limited ( ONC ), the world's largest Omega - 3 EPA/DHA solutions provider, and supplier of MEG - 3( R ) brand Omega - 3 EPA/DHA ( eicosapentaenoic acid/docosahexaenoic acid ) ingredients, is pleased to announce that it has entered into an exclusive (...) |
| 2008-03-31: |
Lilly Launches Its First Phase III Trial for Treatment of Alzheimer's Disease
Indianapolis ( PRN/ots ) - - Late - stage IDENTITY study of once - daily, oral agent is now enrolling patients Eli Lilly and Company ( NYSE: LLY ) has announced today the start of a Phase III clinical trial studying LY450139, an investigational gamma secretase inhibitor for the (...) |
| 2004-09-02: |
Prometic's Lead Cancer Compound PBI - 1402 Has Confirmed Activity on Red Blood Cell Progenitors
Montreal ( PRN/ots ) - - Potential use Includes Anaemia Induced by Chemotherapy and Renal Diseases - Market of Above US$10 Billion ProMetic Life Sciences Inc. ( TSX: PLI ) is pleased to announce that its scientists have confirmed evidence of PBI - 1402's positive effect on the formation (...) |
| 2008-05-16: |
Eribulin Mesylate Demonstrated Anti - Tumor Activity in Heavily Pretreated Patients With Advanced Breast Cancer
London ( PRN/ots ) - - Phase II Data Presented at ASCO Showed Acceptable Tolerability Profile, with Low Incidence of Grade 3 and 4 Neuropathy Eisai Europe Ltd. The investigational chemotherapeutic agent eribulin mesylate ( E7389 ) demonstrated activity in a heavily pretreated population of women with (...) |
| 2007-06-18: |
New Study Shows That telmisartan has Greater Renoprotective Potential Than losartan in Hypertensive Patients With Type 2 Diabetes
Milan, Italy ( PRN/ots ) - - For non - US Healthcare Media Today AMADEO, one of the first studies to compare the protective potential of two angiotensin receptor blockers in hypertensive patients with diabetic nephropathy, was presented at the European Society of Hypertension, Milan. The (...) |
| 2008-01-18: |
Novagali Pharma Announces FDA Clearance of IND for US Clinical Trial of Nova63035 in Patients With Diabetic Macular Edema
Evry, France ( PRN/ots ) - - Not for Distribution in the United States, Canada or Japan Novagali Pharma, an emerging ophthalmic pharmaceutical company announced today that the Company's Investigational New Drug Application ( IND ) to conduct a Phase I clinical trial of its Nova63035, an (...) |
| 2011-03-04: |
/C O R R E C T I O N - - Bristol - Myers Squibb and AstraZeneca/
Paris and London ( PRN/ots ) - In the news release, "ONGLYZA( R ) Becomes the First DPP - 4 Inhibitor Available for Use in Europe" issued on 4 Mar 2011 08:00 GMT, by Bristol - Myers Squibb and AstraZeneca NYSE:AZN over PR Newswire, we would like (...) |
| 2010-06-26: |
ONGLYZA( TM ) ( saxagliptin ) With Metformin As Initial Combination Therapy Provided 76 - Week Long - Term Glycemic Control In Treatment - Naive Adults With Type 2 Diabetes
Orlando, Florida, June 26, 2010 ( PRN/ots ) - Bristol - Myers Squibb Company and AstraZeneca today announced results up to 76 - weeks from a Phase 3 study of ONGLYZA( TM ) ( saxagliptin ) as initial combination therapy with metformin, which produced long - term glycemic improvement [as measured by glycosylated (...) |
| 2008-06-11: |
New Meta - Analysis Confirms Safety Profile for NeoRecormon in Treating Anaemia in Cancer Patients
Basel, Switzerland ( PRN/ots ) - - Data Published in the British Journal of Cancer Reports That NeoRecormon use has no Negative Impact on Overall Survival or Tumour Progression A new meta - analysis of all 12 prospective, randomised, controlled studies in 2,301 cancer patients shows (...) |
| 2006-09-14: |
Safety and Efficacy of Drug - Eluting Stents Reaffirmed in New England Journal of Medicine Articles and Editorial
Natick, Massachusetts ( PRN/ots ) - Boston Scientific Corporation ( NYSE: BSX ) today welcomed the results of two studies and an editorial published in today's edition of The New England Journal of Medicine ( NEJM ), all of which reaffirmed the safety and efficacy of drug - eluting stents. Commenting (...) |
| 2006-06-19: |
Anticipated Approval of Latest HIV Drug Will Give Treatment - Experienced Patients the Best Chance Yet to Achieve Undetectable Viral Load
Basel, Switzerland ( PRN/ots ) - - Newest HIV Drug Works Better in Combination With FUZEON( R ) The emergence of new HIV treatments, such as boosted protease inhibitors ( PI ), has led to a change in treatment goals for people living with drug - resistant HIV. Up (...) |
| 2011-03-30: |
Astellas and Medivation Announce Initiation of Phase 2 Clinical Trial Comparing MDV3100 With Bicalutamide in Advanced Prostate Cancer
LONDON, STAINES, England and SAN FRANCISCO, March 30, 2011 ( PRN/ots ) - - Astellas Pharma Europe Ltd. and Medivation, Inc. today announced treatment of the first patient in the TERRAIN trial, a Phase 2 comparison of the investigational drug MDV3100, a triple - acting, oral androgen receptor (...) |
| 2007-08-01: |
MDS Pharma Services Expands Development & Regulatory Services in Europe
King Of Prussia, Pennsylvania ( PRN/ots ) - MDS Pharma Services, a leading provider of innovative drug discovery and development solutions, announced today the expansion of its Development & Regulatory Services ( DRS ) business in Europe. MDS Pharma Services will now offer full - service DRS consulting services to (...) |
| 2011-02-15: |
The World Heart Federation, sanofi - aventis and Boehringer Ingelheim Announce Collaboration on Worldwide AF Awareness Campaign
Geneva ( PRN/ots ) - The World Heart Federation, sanofi - aventis and Boehringer Ingelheim have announced their collaboration on the AF AWARE ( Atrial Fibrillation AWareness And Risk Education ) campaign today, to raise awareness of atrial fibrillation ( AF ) and its links to severe consequences including cardiovascular ( CV ) mortality, (...) |
| 2009-01-13: |
The Turkish Government Adds Wyeth's 7 - valent Pneumococcal Conjugate Vaccine ( PCV7 ) to Their National Immunisation Schedule
Maidenhead, England ( PRN/ots ) - - Prevenar Vaccine to Help Protect Children Against the Leading Vaccine - Preventable Cause of Death in Young Children Worldwide Turkey has initiated a national immunization programme ( NIP ) against pneumococcal disease with Wyeth's Prevenar( TM ) ( Pneumococcal saccharide conjugated vaccine, Adsorbed ) - a (...) |
| 2005-04-06: |
Isotechnika Receives U.S. Patent for Insulin Resistance Diagnostic Test
Edmonton, Canada ( PRN/ots ) - Isotechnika Inc. ( TSX: ISA ) announced today that the Company has been issued U.S. Patent No. 6,878,550 for its diagnostic breath test kit, Diatest( R ). The patent entitled "13C Glucose Breath Test for the Diagnosis of Diabetic Indications and Monitoring Glycemic Control" (...) |
| 2008-09-16: |
New Data Confirms Avastin ( R ) as the Only Biologic to Demonstrate Overall Survival When Used First - Line in Metastatic Colorectal Cancer Patients With K - RAS ( Wild - Type ) Gene Status
Basel, Switzerland ( PRN/ots ) - Avastin ( bevacizumab ) remains the only biologic to provide overall survival ( OS ) benefit when used as first - line treatment in combination with chemotherapy for patients with K - Ras wild type metastatic colorectal cancer ( mCRC ). Avastin's strong position was confirmed today following new (...) |
| 2006-10-13: |
Roche Progresses its Oral Polymerase Inhibitor Into Phase II Development Study in Patients With Hepatitis C
Basel, Switzerland ( PRN/ots ) - - FDA Grants Fast Track Status to R1626 Roche announced today the start of the first phase II development study to evaluate R1626, their promising new polymerase inhibitor, for the treatment of hepatitis C. The investigational drug has (...) |
| 2008-10-12: |
Europeans Face a Painful Truth on First Ever Neuropathic Pain Day - October 13
London ( PRN/ots ) - - Not for UK Journalists - New Survey Reveals Widespread Ignorance of Debilitating Pain Condition Affecting Millions of Europeans Alarmingly, nearly sixty per cent of Europeans have never heard of neuropathic pain ( NeP ), ( 1 ) a debilitating nerve condition that affects approximately (...) |
| 2010-04-19: |
Stallergenes: Positive Results for Oralair( R ) Phase III Trial in the USA
Antony, France, April 19, 2010 ( PRN/ots ) - Stallergenes S.A. today announced the first results of a phase III clinical trial ( VO61.08 ) conducted in the USA on its sublingual grass pollen immunotherapy tablet, Oralair( R ). This phase III study is the first clinical study in (...) |
| 2011-01-12: |
Daiichi Sankyo and ArQule Enroll First Non - Small Cell Lung Cancer Patient Into Global Phase III Trial for ARQ 197
Tokyo and Woburn, Massachusetts ( PRN/ots ) - Daiichi Sankyo Company, Limited ( TSE 4568 ) and ArQule, Inc. today announced that the first patient has been enrolled in the phase III trial of ARQ 197, an investigational selective inhibitor of the c - Met receptor tyrosine kinase, (...) |
| 2009-05-28: |
Agendia Supports Genentech's Citizen's Petition Urging FDA to Hold In - Vitro Diagnostic Tests to One Set of Scientific and Regulatory Standards
Huntington Beach, California, and Amsterdam ( PRN/ots ) - Agendia, a world leader in molecular cancer diagnostics, today announced its strong support of Genentech's Citizen's Petition. Filed on December 5, 2008, Docket No. FDA - 2008 - P - 0638 - 0001/CP petitions that all in vitro diagnostic (...) |
| 2005-06-20: |
New Study Adds Weight to Clinical Merit of MENOPUR in IVF
Copenhagen, Denmark ( PRN/ots ) - - "Approximately five more pregnancies per 100 women treated" with MENOPUR compared to recombinant treatment New data presented today at the ESHRE ( European Society of Human Reproduction and Embryology ) congress supports the efficacy of MENOPUR ( menotrophin ), a highly purified, (...) |
| 2011-04-19: |
Investors Flock to German Medical Biotech Industry / BayBio Annual Conference
Berlin / Burlingame ( California ) ( na Originaltextservice ) - Germany is setting the bar in biotechnology and investors from all over the world are taking notice. Venture capital investments doubled from 2009 to 2010 to over $420 million. Industry revenues continue to grow, according to (...) |
| 2008-06-25: |
Leading Colorectal Patient Organisation Calls on EU Countries to Improve Poor Standards of Care
Barcelona, Spain ( PRN/ots ) - europacolon has called on all governments to implement existing EU recommendations on colorectal cancer screening following a new report published today that shows the disease to be significantly neglected despite being the second most common cancer in Europe.( 1 ) Welcoming the (...) |
|
| back...
1
2
3
4
5
6
7
8
9
10
11
more... |
